Immatics Biotechnologies Gmbh Stock Today
| IMTXW Stock | USD 0.02 0.01 33.67% |
PerformanceVery Weak
| Odds Of DistressLow
|
Immatics Biotechnologies is selling for under 0.0199 as of the 25th of March 2025; that is 33.67 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0199. Immatics Biotechnologies has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of July 2020 | Category Healthcare | Classification Health Care |
Immatics Biotechnologies is entity of United States. It is traded as Stock on NASDAQ exchange. More on immatics biotechnologies GmbH
Moving together with Immatics Stock
Moving against Immatics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Immatics Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immatics Biotechnologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immatics Biotechnologies' financial leverage. It provides some insight into what part of Immatics Biotechnologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
immatics biotechnologies GmbH (IMTXW) is traded on NASDAQ Exchange in USA. It is located in Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076 and employs 572 people. Immatics Biotechnologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 673 M. Immatics Biotechnologies classifies itself under Biotechnology sector and is part of Health Care industry.
Immatics Biotechnologies generates positive cash flow from operations, but has no cash available
Check Immatics Biotechnologies Probability Of Bankruptcy
Immatics Biotechnologies Historical Income Statement
Immatics Stock Against Markets
Immatics Biotechnologies Corporate Management
| Andrea Mokler | VP Sciences | Profile | |
| Miriam Meyer | VP Affairs | Profile | |
| Edward Sturchio | General Secretary | Profile | |
| Arnd MBA | Chief Officer | Profile | |
| Toni Weinschenk | CoFounder Officer | Profile | |
| Thomas Ulmer | Chief Officer | Profile |
Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.